Search Medical Condition
Please enter condition
Please choose location

Angina Clinical Trials

A listing of Angina medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (94) clinical trials

Physiologic Assessment of Coronary Stenosis Following PCI

This is a pilot study designed to assess the relationship between iFR pullback and the distribution of coronary atheroma/stenoses as assessed by Quantitative Coronary Angiography (QCA) post angiographically successful PCI.

Phase N/A

To Evaluate Safety and Efficacy of CGBIO Stent Compared to Biomatrix Flex Stent

A Multicenter, subject-blinded, randomized study to evaluate safety and efficacy of CGBIO stent compared to Biomatrix Flex stent in patients undergoing drug-eluting stent procedure after coronary angiography

Phase N/A

Effect and Efficacy of Onyx Zotarolimus-eluting Stent for Coronary Atherosclerosis

Secondary endpoints are Stent thrombosis-24 hours(acute), 30 days(subacute), 1 year(late), every 1 year till 3 years(very-late) after index PCI (percutaneous coronary intervention), Target vessel failure Composite rate of cardiac death and any MI, 3 years Composite rate of all death and any MI Composite rate of all death, any MI, ...

Phase N/A

SORT OUT X - Combo Stent Versus ORSIRO Stent

Randomized Clinical Comparison of a Combined Sirolimus Eluting and endothelial progenitor cell COMBO Stent with a Sirolimus-eluting OSIRO stent in Patients Treated with Percutaneous Coronary Intervention.

Phase N/A

Early Outcome in Unstable Angina Patients With Low EF After CABG

Current treatment options for Chronic Unstable Angina patients with low Ejection Fraction include intensive medical therapy, surgical revascularization, ventricular remodeling, and heart transplantation. Medical treatment alone is problematic because of limited long-term survival. Heart transplantation offers excellent results with a 65.6 % 5-year survival rate; however, the scarcity of donor ...

Phase N/A

Feasibility and Outcomes of Complete Coronary Revascularization Using BVS in All-comer Patients With Angina

Study design: Data regarding all consecutive patients qualified for revascularization (PCI Percutaneous Coronary Intervention or CABG Coronary Artery Bypass Grafting) will be collected in this prospective study. Information regarding revascularization strategy will be collected as detailed information concerning PCI procedure. In case of PCI with other than BVS stent implantation ...

Phase N/A

Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome

Evaluate the ability of ranolazine to favorably modify thrombogenic, inflammatory, lipogenic, oxidative stress and hormonal biomarkers in a relatively short period of time in a group of ethnically diverse women with chronic stable angina and metabolic syndrome. Evaluate the ability of ranolazine to favorably decrease angina frequency and nitroglycerine use ...


Heart Rate Variability (HRV) Testing Compared With Exercise Stress Test in Hospitalized Patients With Chest Pain

Ischemic heart disease is among the leading causes of death and disability in the modern world. Effective treatment for cardiac ischemia is based on identification of the proper patients and assigning prompt treatment to those patients. It is not simple identifying the proper patients. There are many patients complaining of ...

Phase N/A

GLP-1 Loading During Elective Percutaneous Coronary Intervention

Angina is caused by narrowings or blockages within coronary arteries. Coronary angioplasty and stenting is performed for people with angina to improve the blood supply to the heart by placing metal tubes within the artery using balloon inflation. The procedure risks small but significant damage to the heart muscle downstream ...


Drug Eluting Balloon for Treatment of Unstable Angina

Patients with unstable angina were randomized to drug eluting stent only or drug eluting balloon group. Angiographic follow-up was performed after 12 months. The primary endpoints were late lumen loss (LLL) and the secondary endpoints were target lesion revascularization (TLR),and the major adverse cardiovascular events (MACE) .

Phase N/A